Researchers at the Olivia Newton-John Cancer Research Institute in Melbourne, Australia, are accelerating the search for cancer treatments that are both more effective and far less punishing for patients, powered by a new data platform that helps scientists make sense of vast genomic datasets. The institute’s May “Imagine” fundraising campaign aims to secure funding for therapies that better distinguish cancer cells from healthy tissue, reducing the life-altering side effects that many patients endure.
Central to this effort is a partnership with Qumulo, a data management company whose cloud platform allows researchers to analyze enormous volumes of genomic sequences, tumor images, and clinical trial records with greater speed and precision. The technology helps transform raw data into personalized treatments, an approach that could lead to therapies tailored to an individual patient’s cancer rather than a one-size-fits-all regimen. “When data flows without friction, researchers can focus on saving and improving lives,” said Michelle Palleschi, Chief Operating Officer at Qumulo.
The institute has made notable progress in the past year. Scientists have engineered next-generation nanoparticles capable of delivering cancer drugs with far greater accuracy. Their CRISPR platform, called MAGEC, has produced more than 400 animal models of disease, which have been distributed to hundreds of laboratories worldwide and contributed to more than 100 published studies. These tools allow researchers to track cancer cells with genetic barcodes and model nanoparticle delivery in live animals, generating data that requires robust infrastructure to manage.
Throughout May, the institute is inviting individuals, businesses, and organizations to donate through the Imagine Appeal, with funds going directly to research programs focused on discovering gentler cancer therapies. For Qumulo, which has supported the institute as a customer for years, the campaign is a reminder of the human impact behind the data. “Behind every data point is a cancer patient, their cancer journey and the next research breakthrough,” the company noted. The partnership highlights how advances in data management are helping turn scientific ambition into real-world progress for patients.